CytoDyn raises $9.9M through private placement
Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A
Commercial Banking: June 22nd Edition
Understanding Loss Given Default A Review of Three Approaches
Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy
Vancouver, Wash.-based CytoDyn Inc. raised approximately $9.9 million via the sale of 19,823,260 units at 50 cents apiece.
Each unit was made up of a common share and a warrant to purchase an additional stock at 75 cents each.
CytoDyn is developing treatments for HIV.